Medarex and Lonza sign agreement for supply of antibody products
Swiss pharmaceutical firm Lonza and US-based Medarex are to collaborate on the development and commercialisation of Medarex\'s pipeline of therapeutic proteins and antibody drug conjugates (ADCs).
Swiss pharmaceutical firm Lonza and US-based Medarex are to collaborate on the development and commercialisation of Medarex's pipeline of therapeutic proteins and antibody drug conjugates (ADCs).
As part of the agreement, Lonza may provide process development services for some Medarex programmes and reserve manufacturing capacity for Medarex antibody and antibody drug conjugate programmes at its biopharmaceutical facilities worldwide. Further details were not revealed.
"Supporting Medarex's immediate and long-term needs with our expertise in mammalian cell culture and antibody drug conjugates is both exciting and rewarding," said Dr Stephan Kutzer, head of Lonza Biopharmaceuticals.
Medarex's biologics portfolio is focused on treating oncology and immunology therapeutic indications with ten antibody programmes in Phase III to I clinical development. There are more than 40 therapeutic product candidates derived from the company's UltiMAb technology in development or at the IND submission stage for clinical trials, either through its internal efforts or through partnerships. Under the terms of the agreement, Lonza may support a portion of the Medarex product pipeline.